Atumelnant Pivotal Trial for Adult CAH Doses First Patient
Phase 2 data for atumelnant in adults with classic congenital adrenal hyperplasia (CAH) showed rapid, substantial and sustained reductions...
Rapid Resolution Lifts Hold on Tenaya’s Gene Therapy Trial
FDA has lifted the clinical hold on Tenaya’s MyPEAK-1 Phase 1b/2a trial of TN-201 in MYBPC3-associated hypertrophic cardiomyopathy, with...
Akari Therapeutics Starts GMP Manufacturing for Phase 1 Trial
Akari Therapeutics has initiated GMP manufacturing for AKTX-101, its Trop2-targeted antibody-drug conjugate built around a proprietary spliceosome-modulating payload (PH1)....
Quantum Biopharma Completes Dosing in Lucid-MS Toxicity Study
Quantum BioPharma has completed oral dosing in 180-day chronic toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS), its preclinical remyelination...
Immuneering to Post Survival Data in Pancreatic Cancer Trial
No new efficacy data were released, but Immuneering set January 7, 2026, for a 12‑month overall survival update from...
INVIVYD Launches Phase 3 Trial for COVID Antibody VYD2311
In earlier Phase 1/2 testing, intramuscular VYD2311 given at four times the planned Phase 3 dose was well tolerated,...
Lapix Doses First Patient in Phase 1b Dermatitis Trial
LAPIX Therapeutics has dosed the first patient in a randomized, placebo-controlled Phase Ib study of LPX-TI641 in adults with...
Promising Lupus Drug LBL-047 Enters Phase 1 Trial
No efficacy data yet. Leads Biolabs and Dianthus have dosed the first subject in a double-blind, randomized, placebo-controlled Phase...
Remarkable Corneal Nerve Outcomes in Phase 2 Pain Study
In a randomized, double-masked Phase 2 trial in neuropathic corneal pain (NCP), patients treated with 0.05% urcosimod showed exploratory,...
Orelabrutinib SLE Study Meets Phase IIb Goal, Enters Phase III
In a 187-patient Phase IIb study in systemic lupus erythematosus (SLE), orelabrutinib 75 mg once daily achieved a 57.1%...